<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03277222</url>
  </required_header>
  <id_info>
    <org_study_id>REB17-0104</org_study_id>
    <secondary_id>Control# 204512</secondary_id>
    <nct_id>NCT03277222</nct_id>
  </id_info>
  <brief_title>Intranasal Treatment of HIV-associated Neurocognitive Disorders</brief_title>
  <official_title>HAND IN Insulin-001: Intranasal Treatment of HIV-associated Neurocognitive Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Epidemiology Coordinating and Research Centre, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Calgary</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to see whether intranasal insulin is an effective treatment for problems with
      memory, concentration, slowed thinking, or any other cognitive function in people living with
      HIV/AIDS. This group of signs and symptoms are called 'HIV-associated neurocognitive
      disorders' or HAND. HAND can affect people living with HIV/AIDS even when they receive potent
      anti-HIV treatments. Treatment of HAND by specific medication or other means is not yet
      available. Intranasal insulin treatment has virtually no side-effects, and has already been
      tested in people with Alzheimer's disease, where it showed beneficial effects on memory, mood
      and quality of life
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed as a prospective, double-blinded, dose-ranging pilot study of
      intranasal (IN) insulin versus placebo in people with HAND (n = 45) on stable ART medication.
      Participants will be randomly assigned to one of three groups: 20 IU IN insulin R twice
      daily, 40 IU IN insulin R twice daily, or matched-volume placebo, which will be administered
      by dose escalation over 4 weeks (10→20 IU or 10→20→30→40 IU twice daily), taken after
      breakfast and again after dinner using a nasal delivery device. Each escalated dose will be
      given for 1 week. Serum glucose will be tested for hypoglycemia one hour after the initial
      administration of each dose. If no side effects are reported, the dose will be escalated each
      week to a final dose of 20 or 40 IU in week 4. If a higher dose is not tolerated, dose will
      be de-escalated to the tolerated level.

      The objectives of this study are as follows:

      Primary: Determine if IN insulin treatment administered twice daily for 4 months reduces
      overall neurocognitive deficits (based on the global z-score in people with HAND).

      Secondary: Measure effects of IN insulin on individual neuropsychological domains (e.g.,
      memory, processing speed, executive functions, motor functions) and on HAND disease
      progression; Define impacts of IN insulin on quality of life and mood in people with HAND;
      Investigate IN insulin's effects on HAND biomarker profiles in urine and blood.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Arm 1: Drug: IN insulin Dose: Twice daily IN insulin R at 20 IU (n=15) twice daily using a nasal delivery device. IN insulin R diluted with Lilly diluent will be administered by dose escalation over 4 weeks (10→20 IU). Each escalated dose will be given for 1 week.
Arm 2: Drug: IN insulin Dose: Twice daily IN insulin R at 40 IU (n=15), twice daily using a nasal delivery device. IN insulin R diluted with Lilly diluent will be administered by dose escalation over 4 weeks (10→20 IU). Each escalated dose will be given for 1 week.
Arm 3: Drug: IN Lilly diluent Dose: Placebo (Lilly diluent, matched volume; (n=15) twice daily using nasal delivery device.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>This is a prospective dose-ranging double-blinded pilot study over 4 months. At enrolment, participants and their physicians will be blinded to treatment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Global Neurocognitive Performance from Baseline</measure>
    <time_frame>18 weeks</time_frame>
    <description>Change in overall neurocognitive function as measured by the global z score. The global z score is one measurement calculated as the average of z scores from each domain tested.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Neurocognitive Performance: Memory</measure>
    <time_frame>18 weeks</time_frame>
    <description>Change from baseline in the overall z score for the memory domain, calculated as the average of z scores from: Hopkins Verbal Learning Test, Logical Memory Test, and Brief Visual Memory Test (immediate and delayed recall).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Neurocognitive Performance: Executive Function</measure>
    <time_frame>18 weeks</time_frame>
    <description>Change from baseline in the overall z score for the executive function domain, calculated as the average of z scores from: D-KEFS Trail-making Task (Letter-Switching) and Color-Word Interference (Stroop).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Neurocognitive Performance: Attention</measure>
    <time_frame>18 weeks</time_frame>
    <description>Change from baseline in the overall z score for the attention domain, calculated as the average of z scores from: Symbol Digit Modalities Test, D-KEFS Trail-making Test (Number), and Color-Word Interference (Color and Word Reading).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Neurocognitive Performance: Motor Function</measure>
    <time_frame>18 weeks</time_frame>
    <description>Change from baseline in the overall z score for the motor function domain, calculated as the average of z scores from: grooved pegboard completion times for dominant and non-dominant hands.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Neurocognitive Performance: Language</measure>
    <time_frame>18 weeks</time_frame>
    <description>Change from baseline in the overall z score for the language domain, calculated as the average of z scores from: D-KEFS Letter and Category Verbal Fluency Tasks</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from baseline in HQoL questionnaire score</measure>
    <time_frame>18 weeks</time_frame>
    <description>Change from baseline in health-related quality of life (HQoL) questionnaire score</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in the PHQ-9 Questionnaire score</measure>
    <time_frame>18 weeks</time_frame>
    <description>Change in the Patient Health Questionnaire-9 (PHQ-9) depressive symptoms score.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from Baseline in the Frailty Index Score - questionnaire and clinic assessment</measure>
    <time_frame>16 weeks</time_frame>
    <description>Change in the overall Frailty Index score measured from baseline to Week 8.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from Baseline HAND inflammasome biomarker laboratory result profile</measure>
    <time_frame>16 weeks</time_frame>
    <description>Change in inflammasome biomarker laboratory result profile between baseline and week 16.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from Baseline HAND metabolomics biomarker laboratory result profile</measure>
    <time_frame>16 weeks</time_frame>
    <description>Change in metabolomics biomarker laboratory result profile between baseline and week 16.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from Baseline plasma HIV-1 viral load laboratory result</measure>
    <time_frame>16 weeks</time_frame>
    <description>Change in plasma HIV-1 viral load between baseline and week 16.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from Baseline blood CD4 T-cell count laboratory result</measure>
    <time_frame>16 weeks</time_frame>
    <description>Change in blood CD4 T-cell count between baseline and week 16.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>HIV Associated Neurocognitive Disorder (HAND)</condition>
  <arm_group>
    <arm_group_label>IN insulin 20 IU</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: IN insulin Dosage form: intranasal Dose: 20 IU Frequency: bid Duration: 16 weeks dose escalation over 4 weeks 10→20 IU twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IN insulin 40 IU</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: IN insulin Dosage form: intranasal Dose: 40 IU Frequency: bid Duration: 16 weeks dose escalation over 4 weeks 10→20→30→40 IU twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IN Lilly diluent</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: Lilly diluent Dosage form: intranasal Frequency: bid Duration: 16 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IN insulin</intervention_name>
    <description>IN insulin twice daily taken after breakfast and again after dinner using the a nasal delivery device. Each escalated dose will be given for 1 week.</description>
    <arm_group_label>IN insulin 20 IU</arm_group_label>
    <arm_group_label>IN insulin 40 IU</arm_group_label>
    <other_name>Intranasal Humulin R</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IN Lilly Diluent</intervention_name>
    <description>Lilly Diluent twice daily taken after breakfast and again after dinner using the a nasal delivery device.</description>
    <arm_group_label>IN Lilly diluent</arm_group_label>
    <other_name>Intranasal Lilly Diluent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented HIV-1 infection

          -  Maintained on stable ART for ≥6 months (defined as undetectable viral load)

          -  HAND-MND or -ANI diagnosis with evidence of clinical onset or progression within the
             prior 2 years, based on established criteria

          -  Currently followed at the Southern Alberta Clinic (SAC; Calgary, AB, Canada)

        Exclusion Criteria:

          -  HAND with a) changed dose of any medication for HIV-1 infection with a corresponding
             increase in viral load (e.g., ART), or b) secondary therapies for HAND (e.g.,
             memantine, amphetamines).

          -  Advanced liver, renal or lung disease, cancer or diabetes requiring insulin

          -  Secondary diagnosis of neurocognitive impairment or other major neuropsychiatric
             illness such as epilepsy, Alzheimer's or Parkinson's diseases, major depression (PHQ-9
             score &gt;10), or schizophrenia

          -  Central nervous system lesion (diagnosed by neuroimaging) that may impair cognition

          -  Previous allergic reaction to insulin or any of the carrier components.

          -  Education &lt; 9 years or inability to read and write English fluently

          -  Uncontrolled HIV-1 or hepatitis C co-infection

          -  Inability to perform NP or questionnaire measures, functional illiteracy

          -  Past or current substance abuse that could interfere with the study assessments as
             determined by the PI

          -  Marijuana use on the day of NP testing

          -  Uncontrolled cardiovascular disease (hypertension, coronary or peripheral artery
             disease)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Power, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael J Gill, MBChB FACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Calgary</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brenda Beckthold</last_name>
    <phone>403-955-6309</phone>
    <email>Brenda.Beckthold@ahs.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Noshin Koenig</last_name>
    <phone>403-955-6320</phone>
    <email>Noshin.Koenig@ahs.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Southern Alberta Clinic</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2R 0X7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brenda Beckthold</last_name>
      <phone>403-955-6309</phone>
      <email>Brenda.Beckthold@ahs.ca</email>
    </contact>
    <contact_backup>
      <last_name>Noshin Koenig</last_name>
      <phone>403-955-6320</phone>
      <email>Noshin.Koenig@ahs.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Michael J Gill, MBChB FACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christopher Power, MD FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sean Rourke, FCAHS PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ross Tsuyuki, PharmD,FCSHP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Esther Fujiwara, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>https://www.ualberta.ca/department-of-medicine/powerlab</url>
    <description>The Brain Power Lab</description>
  </link>
  <reference>
    <citation>Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007 Oct 30;69(18):1789-99. Epub 2007 Oct 3.</citation>
    <PMID>17914061</PMID>
  </reference>
  <reference>
    <citation>Pandya R, Krentz HB, Gill MJ, Power C. HIV-related neurological syndromes reduce health-related quality of life. Can J Neurol Sci. 2005 May;32(2):201-4.</citation>
    <PMID>16018155</PMID>
  </reference>
  <reference>
    <citation>Yeung H, Krentz HB, Gill MJ, Power C. Neuropsychiatric disorders in HIV infection: impact of diagnosis on economic costs of care. AIDS. 2006 Oct 24;20(16):2005-9.</citation>
    <PMID>17053346</PMID>
  </reference>
  <reference>
    <citation>Vivithanaporn P, Heo G, Gamble J, Krentz HB, Hoke A, Gill MJ, Power C. Neurologic disease burden in treated HIV/AIDS predicts survival: a population-based study. Neurology. 2010 Sep 28;75(13):1150-8. doi: 10.1212/WNL.0b013e3181f4d5bb. Epub 2010 Aug 25.</citation>
    <PMID>20739646</PMID>
  </reference>
  <reference>
    <citation>Mamik MK, Asahchop EL, Chan WF, Zhu Y, Branton WG, McKenzie BA, Cohen EA, Power C. Insulin Treatment Prevents Neuroinflammation and Neuronal Injury with Restored Neurobehavioral Function in Models of HIV/AIDS Neurodegeneration. J Neurosci. 2016 Oct 12;36(41):10683-10695.</citation>
    <PMID>27733618</PMID>
  </reference>
  <reference>
    <citation>Boissé L, Gill MJ, Power C. HIV infection of the central nervous system: clinical features and neuropathogenesis. Neurol Clin. 2008 Aug;26(3):799-819, x. doi: 10.1016/j.ncl.2008.04.002. Review.</citation>
    <PMID>18657727</PMID>
  </reference>
  <reference>
    <citation>Fujiwara, E., Gill, J.M. &amp; Power, C. Risk Factors for HIV-Associated Neurocognitive Disorders (HAND) in a Canadian Cohort (P1.321). Neurology 86 P1.321 (2016).</citation>
  </reference>
  <reference>
    <citation>McCombe JA, Vivithanaporn P, Gill MJ, Power C. Predictors of symptomatic HIV-associated neurocognitive disorders in universal health care. HIV Med. 2013 Feb;14(2):99-107. doi: 10.1111/j.1468-1293.2012.01043.x. Epub 2012 Sep 20.</citation>
    <PMID>22994556</PMID>
  </reference>
  <reference>
    <citation>Grant I, Franklin DR Jr, Deutsch R, Woods SP, Vaida F, Ellis RJ, Letendre SL, Marcotte TD, Atkinson JH, Collier AC, Marra CM, Clifford DB, Gelman BB, McArthur JC, Morgello S, Simpson DM, McCutchan JA, Abramson I, Gamst A, Fennema-Notestine C, Smith DM, Heaton RK; CHARTER Group. Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology. 2014 Jun 10;82(23):2055-62. doi: 10.1212/WNL.0000000000000492. Epub 2014 May 9.</citation>
    <PMID>24814848</PMID>
  </reference>
  <reference>
    <citation>Sacktor N, Skolasky RL, Seaberg E, Munro C, Becker JT, Martin E, Ragin A, Levine A, Miller E. Prevalence of HIV-associated neurocognitive disorders in the Multicenter AIDS Cohort Study. Neurology. 2016 Jan 26;86(4):334-40. doi: 10.1212/WNL.0000000000002277. Epub 2015 Dec 30.</citation>
    <PMID>26718568</PMID>
  </reference>
  <reference>
    <citation>Nightingale S, Winston A, Letendre S, Michael BD, McArthur JC, Khoo S, Solomon T. Controversies in HIV-associated neurocognitive disorders. Lancet Neurol. 2014 Nov;13(11):1139-1151. doi: 10.1016/S1474-4422(14)70137-1. Review.</citation>
    <PMID>25316020</PMID>
  </reference>
  <reference>
    <citation>Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, Gelman BB, McArthur JC, McCutchan JA, Morgello S, Simpson D, Grant I, Ellis RJ; CHARTER Group. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008 Jan;65(1):65-70. doi: 10.1001/archneurol.2007.31.</citation>
    <PMID>18195140</PMID>
  </reference>
  <reference>
    <citation>Hyun E, Ramachandran R, Hollenberg MD, Vergnolle N. Mechanisms behind the anti-inflammatory actions of insulin. Crit Rev Immunol. 2011;31(4):307-40. Review.</citation>
    <PMID>21899513</PMID>
  </reference>
  <reference>
    <citation>Benedict C, Hallschmid M, Hatke A, Schultes B, Fehm HL, Born J, Kern W. Intranasal insulin improves memory in humans. Psychoneuroendocrinology. 2004 Nov;29(10):1326-34.</citation>
    <PMID>15288712</PMID>
  </reference>
  <reference>
    <citation>Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, Arbuckle M, Callaghan M, Tsai E, Plymate SR, Green PS, Leverenz J, Cross D, Gerton B. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol. 2012 Jan;69(1):29-38. doi: 10.1001/archneurol.2011.233. Epub 2011 Sep 12.</citation>
    <PMID>21911655</PMID>
  </reference>
  <reference>
    <citation>Rosenbloom MH, Barclay TR, Pyle M, Owens BL, Cagan AB, Anderson CP, Frey WH 2nd, Hanson LR. A single-dose pilot trial of intranasal rapid-acting insulin in apolipoprotein E4 carriers with mild-moderate Alzheimer's disease. CNS Drugs. 2014 Dec;28(12):1185-9. doi: 10.1007/s40263-014-0214-y.</citation>
    <PMID>25373630</PMID>
  </reference>
  <reference>
    <citation>Claxton A, Baker LD, Wilkinson CW, Trittschuh EH, Chapman D, Watson GS, Cholerton B, Plymate SR, Arbuckle M, Craft S. Sex and ApoE genotype differences in treatment response to two doses of intranasal insulin in adults with mild cognitive impairment or Alzheimer's disease. J Alzheimers Dis. 2013;35(4):789-97. doi: 10.3233/JAD-122308.</citation>
    <PMID>23507773</PMID>
  </reference>
  <reference>
    <citation>Claxton A, Baker LD, Hanson A, Trittschuh EH, Cholerton B, Morgan A, Callaghan M, Arbuckle M, Behl C, Craft S. Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's disease dementia. J Alzheimers Dis. 2015;44(3):897-906. doi: 10.3233/JAD-141791. Erratum in: J Alzheimers Dis. 2015;45(4):1269-70.</citation>
    <PMID>25374101</PMID>
  </reference>
  <reference>
    <citation>Reger MA, Watson GS, Green PS, Wilkinson CW, Baker LD, Cholerton B, Fishel MA, Plymate SR, Breitner JC, DeGroodt W, Mehta P, Craft S. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology. 2008 Feb 5;70(6):440-8. Epub 2007 Oct 17. Erratum in: Neurology. 2008 Sep 9;71(11):866.</citation>
    <PMID>17942819</PMID>
  </reference>
  <reference>
    <citation>Shemesh E, Rudich A, Harman-Boehm I, Cukierman-Yaffe T. Effect of intranasal insulin on cognitive function: a systematic review. J Clin Endocrinol Metab. 2012 Feb;97(2):366-76. doi: 10.1210/jc.2011-1802. Epub 2011 Dec 7. Review.</citation>
    <PMID>22162476</PMID>
  </reference>
  <reference>
    <citation>Asahchop EL, Akinwumi SM, Branton WG, Fujiwara E, Gill MJ, Power C. Plasma microRNA profiling predicts HIV-associated neurocognitive disorder. AIDS. 2016 Aug 24;30(13):2021-31. doi: 10.1097/QAD.0000000000001160.</citation>
    <PMID>27191977</PMID>
  </reference>
  <reference>
    <citation>Lénárt N, Brough D, Dénes Á. Inflammasomes link vascular disease with neuroinflammation and brain disorders. J Cereb Blood Flow Metab. 2016 Oct;36(10):1668-1685. Epub 2016 Aug 2. Review.</citation>
    <PMID>27486046</PMID>
  </reference>
  <reference>
    <citation>Walsh JG, Muruve DA, Power C. Inflammasomes in the CNS. Nat Rev Neurosci. 2014 Feb;15(2):84-97. doi: 10.1038/nrn3638. Epub 2014 Jan 8. Review.</citation>
    <PMID>24399084</PMID>
  </reference>
  <reference>
    <citation>Kim DH, Jewison DL, Milner GR, Rourke SB, Gill MJ, Power C. Neurocognitive symptoms and impairment in an HIV community clinic. Can J Neurol Sci. 2001 Aug;28(3):228-31.</citation>
    <PMID>11513341</PMID>
  </reference>
  <reference>
    <citation>Koenig N, Fujiwara E, Gill MJ, Power C. Montreal Cognitive Assessment Performance in HIV/AIDS: Impact of Systemic Factors. Can J Neurol Sci. 2016 Jan;43(1):157-62. doi: 10.1017/cjn.2015.306. Epub 2015 Dec 4.</citation>
    <PMID>26635008</PMID>
  </reference>
  <reference>
    <citation>Fujiwara E, Tomlinson SE, Purdon SE, Gill MJ, Power C. Decision making under explicit risk is impaired in individuals with human immunodeficiency virus (HIV). J Clin Exp Neuropsychol. 2015;37(7):733-50. doi: 10.1080/13803395.2015.1057481. Epub 2015 Jul 24.</citation>
    <PMID>26207583</PMID>
  </reference>
  <reference>
    <citation>Justice AC, McGinnis KA, Atkinson JH, Heaton RK, Young C, Sadek J, Madenwald T, Becker JT, Conigliaro J, Brown ST, Rimland D, Crystal S, Simberkoff M; Veterans Aging Cohort 5-Site Study Project Team. Psychiatric and neurocognitive disorders among HIV-positive and negative veterans in care: Veterans Aging Cohort Five-Site Study. AIDS. 2004 Jan 1;18 Suppl 1:S49-59.</citation>
    <PMID>15075498</PMID>
  </reference>
  <reference>
    <citation>Crane HM, Van Rompaey SE, Dillingham PW, Herman E, Diehr P, Kitahata MM. A single-item measure of health-related quality-of-life for HIV-infected patients in routine clinical care. AIDS Patient Care STDS. 2006 Mar;20(3):161-74.</citation>
    <PMID>16548713</PMID>
  </reference>
  <reference>
    <citation>Power C, Gill MJ, Johnson RT. Progress in clinical neurosciences: The neuropathogenesis of HIV infection: host-virus interaction and the impact of therapy. Can J Neurol Sci. 2002 Feb;29(1):19-32. Review.</citation>
    <PMID>11858531</PMID>
  </reference>
  <reference>
    <citation>Van Marle G, Rourke SB, Zhang K, Silva C, Ethier J, Gill MJ, Power C. HIV dementia patients exhibit reduced viral neutralization and increased envelope sequence diversity in blood and brain. AIDS. 2002 Sep 27;16(14):1905-14.</citation>
    <PMID>12351950</PMID>
  </reference>
  <reference>
    <citation>Skinner S, Adewale AJ, DeBlock L, Gill MJ, Power C. Neurocognitive screening tools in HIV/AIDS: comparative performance among patients exposed to antiretroviral therapy. HIV Med. 2009 Apr;10(4):246-52. doi: 10.1111/j.1468-1293.2008.00679.x. Epub 2009 Jan 23.</citation>
    <PMID>19187172</PMID>
  </reference>
  <reference>
    <citation>McCombe JA, Auer RN, Maingat FG, Houston S, Gill MJ, Power C. Neurologic immune reconstitution inflammatory syndrome in HIV/AIDS: outcome and epidemiology. Neurology. 2009 Mar 3;72(9):835-41. doi: 10.1212/01.wnl.0000343854.80344.69.</citation>
    <PMID>19255411</PMID>
  </reference>
  <reference>
    <citation>Sacktor, N., et al. Paroxetine and Fluconazole Therapy for HAND: A Double-Blind, Placebo-Controlled Trial. Conference on retroviruses and opportunistic infections. 2016 Boston MA USA Sesssion O-12 Abstract 146(2016).</citation>
  </reference>
  <reference>
    <citation>Power C, Boissé L, Rourke S, Gill MJ. NeuroAIDS: an evolving epidemic. Can J Neurol Sci. 2009 May;36(3):285-95. Review.</citation>
    <PMID>19534327</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 28, 2017</study_first_submitted>
  <study_first_submitted_qc>September 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 8, 2017</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Calgary</investigator_affiliation>
    <investigator_full_name>John Gill</investigator_full_name>
    <investigator_title>Medical Director, Southern Alberta Clinic</investigator_title>
  </responsible_party>
  <keyword>Neurocognitive impairment</keyword>
  <keyword>HIV-1</keyword>
  <keyword>Intranasal insulin</keyword>
  <keyword>Neurocognitive Disorder</keyword>
  <keyword>Cognition</keyword>
  <keyword>Memory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Neurocognitive Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

